SOHO 2021 | An overview of the MDS diagnosis pathway
Andrew Brunner
• 13 Sep 2021
Andrew Brunner, MD, of Massachusetts General Hospital, Boston, MA, process of diagnosing myelodysplastic syndromes (MDS). Currently, bone marrow aspirates and biopsies are taken to investigate the presence of abnormal-looking plasma cells alongside a full cytogenetic assessment and a molecular assessment of the blood. Dr Brunner also talks on the value of genetic mutations for the diagnosis of MDS, with SF3B1 mutations being able to identify certain subtypes of MDS. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
